p.82 抽出テキスト

10. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 2024;45:3415–537. https://doi.org/10.1093/eurheartj/ehae177 11. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 2021;23:352–80. https://doi.org/10.1002/ ejhf.2115 12. Becher PM, Lund LH, Coats AJS, Savarese G. An update on global epidemiology in heart failure. Eur Heart J 2022;43:3005–7. https://doi.org/10. 1093/eurheartj/ehac248 13. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272–87. https://doi.org/10.1093/ cvr/cvac013 14. Emmons-Bell S, Johnson C, Roth G. Prevalence, incidence and survival of heart failure: a systematic review. Heart 2022;108:1351–60. https://doi. org/10.1136/heartjnl-2021-320131 15. Seferovic PM, Polovina M, Savarese G, Milinkovic I, Stanisavljevic D, Lund L, et al. Insights into the European heart failure epidemiology. Eur J Heart Fail 2025;27:1950–60. https://doi.org/10.1002/ejhf.3710 16. Christiansen MN, Kober L, Weeke P, Vasan RS, Jeppesen JL, Smith JG, et al. Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation 2017;135:1214–23. https://doi.org/ 10.1161/CIRCULATIONAHA.116.025941 17. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet 2018;391:572–80. https://doi.org/10. 1016/S0140-6736(17)32520-5 18. Wei S, Miranda JJ, Mamas MA, Zuhlke LJ, Kontopantelis E, Thabane L, et al. Sex differences in the etiology and burden of heart failure across country income level: analysis of 204 countries and territories 1990–2019. Eur Heart J Qual Care Clin Outcomes 2023;9:662–72. https://doi.org/10.1093/ehjqcco/ qcac088 19. Barasa A, Schaufelberger M, Lappas G, Swedberg K, Dellborg M, Rosengren A. Heart failure in young adults: 20-year trends in hospitalization, aetiology, and case fatality in Sweden. Eur Heart J 2014;35:25–32. https://doi.org/10. 1093/eurheartj/eht278 20. Lecoeur E, Domeng O, Fayol A, Jannot AS, Hulot JS. Epidemiology of heart failure in young adults: a French nationwide cohort study. Eur Heart J 2023;44:383–92. https://doi.org/10.1093/eurheartj/ehac651 21. Vasan RS, Xanthakis V, Lyass A, Andersson C, Tsao C, Cheng S, et al. Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study: an echocardiographic study over 3 decades. JACC Cardiovasc Imaging 2018;11:1–11. https://doi.org/10.1016/j.jcmg.2017.08. 007 22. Stolfo D, Uijl A, Vedin O, Stromberg A, Faxen UL, Rosano GMC, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. JACC Heart Fail 2019;7:505–15. https://doi.org/10.1016/j.jchf.2019.03.011 23. Peters AE, Tromp J, Shah SJ, Lam CSP, Lewis GD, Borlaug BA, et al. Phenomapping in heart failure with preserved ejection fraction: insights, limitations, and future directions. Cardiovasc Res 2023;118:3403–15. https:// doi.org/10.1093/cvr/cvac179 24. Yang M, Kondo T, Jhund PS, Alcocer-Gamba MA, Borleffs CJW, Chiang CE, et al. Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction. Eur J Heart Fail 2024;26:1788–803. https://doi.org/10.1002/ejhf.3352 25. Garred CH, Malmborg M, Malik ME, Zahir D, Christensen DM, Arulmurugananthavadivel A, et al. Age-specific mortality trends in heart failure over 25 years: a retrospective Danish nationwide cohort study. Lancet Healthy Longev 2024;5:e326–35. https://doi.org/10.1016/S2666- 7568(24)00029-1 26. Lindberg F, Benson L, Dahlstrom U, Lund LH, Savarese G. Trends in heart failure mortality in Sweden between 1997 and 2022. Eur J Heart Fail 2024;27: 366–76. https://doi.org/10.1002/ejhf.3506 27. Conrad N, Judge A, Canoy D, Tran J, Pinho-Gomes AC, Millett ERC, et al. Temporal trends and patterns in mortality after incident heart failure: a longitudinal analysis of 86 000 individuals. JAMA Cardiol 2019;4:1102–11. https://doi.org/10.1001/jamacardio.2019.3593 28. Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol 2017;70:2476–86. https://doi.org/10. 1016/j.jacc.2017.08.074 29. Nichols GA, Reynolds K, Kimes TM, Rosales AG, Chan WW. Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction. Am J Cardiol 2015;116:1088–92. https://doi.org/10.1016/j. amjcard.2015.07.018 30. Arulmurugananthavadivel A, Holt A, Parveen S, Lamberts M, Gislason GH, Torp-Pedersen C, et al. Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017. Eur Heart J Qual Care Clin Outcomes 2022;8:750–60. https://doi.org/10.1093/ehjqcco/qcab073 31. Lindmark K, Boman K, Stalhammar J, Olofsson M, Lahoz R, Studer R, et al. Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: a real-world study. ESC Heart Fail 2021;8:2144–53. https://doi.org/10.1002/ehf2.13296 32. Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail 2017;19:1624–34. https://doi.org/10. 1002/ejhf.945 33. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail 2017;10:e003875. https://doi.org/10.1161/CIRCHEARTFAILURE.117. 003875 34. Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol 2022;19:100–16. https:// doi.org/10.1038/s41569-021-00605-5 35. Rossello X, Prescott EIB, Kristensen AMD, Latini R, Fuster V, Fagerland MW, et al. β Blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet 2025;406:1128–37. https://doi.org/10.1016/S0140- 6736(25)01592-2 36. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26–35. https://doi.org/10.1093/eurheartj/ ehx564 37. Sidiq SA, Truly TA, Minhas AMK, Pickett JK, Suffredini JM, Kayani W, et al. Association between oral beta blocker therapy and long-term outcomes after myocardial infarction in individuals with mildly reduced or preserved left ventricular function: a meta-analysis of contemporary randomized controlled trials. Cardiovasc Drugs Ther 2025. https://doi.org/10.1007/s10557-025-07826-7 38. Alzahrani T, Tiu J, Panjrath G, Solomon A. The effect of angiotensinconverting enzyme inhibitors on clinical outcomes in patients with ischemic cardiomyopathy and midrange ejection fraction: a post hoc subgroup analysis from the PEACE trial. Ther Adv Cardiovasc Dis 2018;12:351–59. https://doi. org/10.1177/1753944718809266 39. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338–45. https://doi.org/10.1093/eurheartj/ehl250 40. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018;20:1230–39. https://doi.org/10.1002/ejhf.1149 41. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362:777–81. https://doi.org/10.1016/S0140-6736(03)14285-7 42. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 2019;381:1609–20. https://doi.org/10.1056/ NEJMoa1908655 43. Jhund PS, Talebi A, Henderson AD, Claggett BL, Vaduganathan M, Desai AS, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet 2024;404:1119–31. https://doi.org/10. 1016/S0140-6736(24)01733-1 44. Jhund PS, Kondo T, Butt JH, Docherty KF, Claggett BL, Desai AS, et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 2022;28:1956–64. https://doi.org/10.1038/s41591-022-01971-4 45. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 2022;43:416–26. https://doi.org/10. 1093/eurheartj/ehab798 Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026